Genentech (San Francisco, CA) has announced an investment exceeding $700m to establish its first East Coast manufacturing facility in Holly Springs, North Carolina. This expansive 700,000ft² facility is set to create over 1,500 construction jobs and more than 400 permanent […]
Genentech to onshore US manufacturing amid rising drug pricing tensions Read More »
UK biopharmaceutical companies saw a surge in venture financing for innovator drugs in 2024, with double the total deal value from 2022: $827m in 2022 to $1.7bn in 2024. This growth trend appears set to continue, with the total deal
UK biopharma innovator venture financing surges to $1.1bn in Q1 2025 Read More »
On 20 May at the American Thoracic Society (ATS) 2025 conference in San Francisco, investigators from the Analysis Group, a multinational consultancy, and GSK presented findings from a retrospective cohort study evaluating asthma patients’ persistence on biologic therapies and their
Real-world cohort study aligns with GSK depemokimab narrative Read More »
On 20 May 2025 at the American Thoracic Society (ATS) International Conference in San Francisco, a poster presentation by GlaxoSmithKline (GSK) provided insight into the therapeutic benefit of depemokimab for improving disease symptoms in patients with asthma. Depemokimab, GSK’s long-acting,
GSK strengthens argument for twice-annual depemokimab Read More »
At the American Thoracic Society (ATS) 2025 Congress on 19 May, Sanofi and Regeneron announced the launch of a new Phase IIIb/IV clinical trial, AIM4, during an evening industry symposium. The trial aims to reassess the entrenched stepwise escalation approach
ATS 2025: Sanofi and Regeneron to launch new AIM4 trial for personalised asthma care Read More »
China’s biopharmaceutical sector saw a rise in oncology drug licensing deals in 2024, particularly for monoclonal antibodies (mAbs) and antibody-drug conjugates (ADCs), with the combined deal value reaching $30 billion. The mAbs and ADCs out-licensed from Chinese biopharmaceutical companies represented
Will trade tensions slow China’s mAb and ADC licensing? Read More »
On 19 May, at the 2025 American Thoracic Society (ATS) International Conference, researchers from Cincinnati Children’s Hospital presented compelling evidence that functional improvement in paediatric cystic fibrosis (CF) patients receiving elexacaftor/tezacaftor/ivacaftor (ETI) therapy is driven by regional clearance of mucus
ATS 2025: ETI-linked mucus clearance tied to lung function gains in paediatric CF Read More »
On 19 May, at the 2025 American Thoracic Society (ATS) International Conference, a poster session by researchers from Ghent University Hospital presented real-world evidence showing that anti–IL-5 biologics significantly reduce both moderate and severe exacerbations in patients with obstructive lung
ATS 2025: Anti–IL-5 therapy cuts exacerbations in coexisting COPD and asthma patients Read More »
On 18 May at the 2025 American Thoracic Society (ATS) International Conference, a poster presentation by Sivagurunathan Sutharsan and colleagues from University Medicine Essen, Ruhrlandklinik, provided compelling long-term efficacy data for elexacaftor/tezacaftor/ivacaftor (ETI) therapy in cystic fibrosis (CF) patients. The
ATS 2025: Real-world data supports Trikafta as gold standard in long-term CF care Read More »
On May 18, at the 2025 American Thoracic Society (ATS) International Conference, updated findings from a post hoc analysis poster presentation of the Phase III MATINEE trial (NCT04133909) reinforced the efficacy of Nucala (mepolizumab) in reducing exacerbations in patients with
ATS 2025: Nucala reduces COPD exacerbations, regardless of severe event history Read More »
